Skip to content

The Role of Synbiotic in the Treatment of Childhood Constipation

The Role of Synbiotic in the Treatment of Childhood Constipation

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT138811193309N1
Enrollment
30
Registered
2010-04-20
Start date
2009-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Other diseases of intestines. Constipation

Interventions

Intervention 1: 1.5 ml/kg/day oral liquid paraffin plus placebo (placebo sachet with the same shape and color to synbiotic). Intervention 2: 1 sachet of synbiotic per day (Restore 1 billion CFU/1 sach
Treatment - Drugs
1.5 ml/kg/day oral liquid paraffin plus placebo (placebo sachet with the same shape and color to synbiotic)
1 sachet of synbiotic per day (Restore 1 billion CFU/1 sachet, Made by Protexin Co. in UK, synbiotic combination were probiotic strains containing L. casei, L. rhamnosus, S. thermophilus, B. breve, L.
1.5 ml/kg/day oral liquid paraffin and 1 sachet of synbiotic per day (Restore 1 billion CFU/1 sachet, Made by Protexin Co. in UK, synbiotic combination were probiotic strains containing L. casei, L. r

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 4-12 years, diagnosis based on Room III criteria as two months of at least 2 or more of the following: less than 2 defecation in the toilet per week, more than 1 episode of fecal incontinence per week, history of retentive posturing or excessive volitional stool retention, history of painful or hard bowel movements, presence of a large fecal mass in the rectum, history of large diameter stools that may obstruct the toilet. Exclusion criteria: presence of organic causes for constipation; including Hirschsprung’s disease, spina bifida occulta, hypothyroidism, cystic fibrosis, neurologic abnormalities and intestinal pseudo-obstruction

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Frequency of bowel movements per week. Timepoint: 4 weeks. Method of measurement: Questionnarie.;Stool consistency. Timepoint: 4 Weeks. Method of measurement: Questionnarie.;Frequency of stool incontinence per week. Timepoint: 4 Weeks. Method of measurement: questionnarie.;Abdominal pain. Timepoint: 4 weeks. Method of measurement: questionnarie.;Painful defecation. Timepoint: 4 weeks. Method of measurement: Questionnarie.

Secondary

MeasureTime frame
Success treatment. Timepoint: 4 weeks. Method of measurement: Success treatment defined as = 3 Bowel Movements per week,= 2 incontinence per month and no abdominal pain.;Adverse effects. Timepoint: 4 weeks. Method of measurement: Questionnarie.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Manijh Khalili

Tehran University of Medical Sciences

dr_khalili2000@yahoo.com+98 21 2213 0265

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026